← Back to Search

Behavioural Intervention

iREACH CDS Tool for Preventing Peanut Allergy (iREACH Trial)

N/A

Waitlist Available

Led By Ruchi S Gupta

Research Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must not have

Practice Sites: Sees <50 newborn patients/year.

Infants: The infant has a medical condition that chronically inhibits the ability to take food orally (i.e., dysphagia, muscular dystrophy, gastrostomy).

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.

Who is the study for?

This trial is for pediatric practices using an integrated EHR, clinicians providing infant care, and caregivers of infants seen for well-child visits at 4 or 6 months. Infants with conditions that risk PPA guideline implementation are excluded, as are temporary clinicians or non-English/Spanish speaking caregivers.

What is being tested?

The iREACH study tests a tool designed to help pediatricians follow guidelines to prevent peanut allergies in children. It's a randomized trial comparing the effectiveness of this tool in reducing peanut allergy incidence by age 2.5 years between intervention and control groups.

What are the potential side effects?

Since iREACH is a decision support tool rather than a medication, it does not have direct side effects like drugs do. However, its impact on clinical practice and patient outcomes related to peanut allergy prevention will be closely monitored.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My practice sees fewer than 50 newborn patients a year.

Select...

My infant cannot eat by mouth due to a long-term health issue.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Pediatric Clinician Adherence to Guidelines

Secondary study objectives

Incidence of Peanut Allergy by Age 2.5

Other study objectives

Allergist Adherence to the Guidelines

Barriers/Facilitators to Guideline Adherence Among Pediatric Clinicians and Caregivers.

Caregiver Adherence to the Guidelines

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention (CDS Tool Integrated)Experimental Treatment1 Intervention

Pediatric clinicians in this arm will receive the iREACH CDS tool and education on the PPA Guidelines to support adherence to the Guidelines.

Group II: Control (No CDS Tool Integrated)Active Control1 Intervention

No study procedures will be implemented in the control practices, and their pediatric clinicians will not receive extra PPA Guidelines education, nor will any EHR modifications be made in their practices to support adherence to PPA Guidelines.

0 / 2Eligibility criteria met